Loading stock data…
$1.30+0.01 (+0.78%)
Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. in the Healthcare sector is trading at $1.30 with a market capitalization of $5M. Wall Street consensus targets $4.00 (1 analysts), implying a +207.7% move over the next 12 months. The stock is currently near its 52-week low of $1.10, remaining 44.0% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$1.93M↓ | -$1.90M↓ | -$1.76M↑ | -$1.77M↑ | -$2.34M |
| Net Income | -$1.85M↑ | -$1.86M↓ | -$1.69M↑ | -$1.70M↑ | -$2.30M |
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment pro...